Clinical Trial Update: First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies [Phase 1, Phase 2]

View source ↗

Summary

First-in-human Phase 1/2 trial of VBC101 by VelaVigo Bio Inc in patients with advanced solid tumor malignancies, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• VBC101

Snippet

Sponsor: VelaVigo Bio Inc | Conditions: Participants With Advanced Solid Tumor Malignancies | Phase 1, Phase 2 | Status: RECRUITING